Editorial: NSAIDs Pharmacogenomics
- PMID: 34867430
- PMCID: PMC8640121
- DOI: 10.3389/fphar.2021.798447
Editorial: NSAIDs Pharmacogenomics
Keywords: adverse drug effects; non-steroidal anti-inflammatory drug (NSAID); pharmacodynamic (PD); pharmacogenomics (PGx); pharmacokinectics & drug metabolism (PDM).
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Comment on
- Editorial on the Research Topic NSAIDs Pharmacogenomics
References
-
- García-Martín E., García-Menaya J. M., Esguevillas G., Cornejo-García J. A., Doña I, Jurado-Escobar R., Torres M. J., Blanca-López N., Canto G., Blanca M., Laguna J. J., Bartra J., Rosado A, Fernández J., Cordobés C., Agúndez J. A. G. (2021). Deep sequencing of prostaglandin-endoperoxide synthase (PTGE) genes reveals genetic susceptibility for cross-reactive hypersensitivity to NSAID. Br J Pharmacol 178 (5), 1218–1233. 10.1111/bph.15366 - DOI - PubMed
-
- Theken K. N., Lee C. R., Gong L., Caudle K. E., Formea C. M., Gaedigk A., Klein T. E., Agúndez J. A. G., Grosser T. (2020). Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2C9 and nonsteroidal anti-inflammatory drugs. Clin Pharmacol Ther 108 (2), 191–200. 10.1002/cpt.1830 - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources